Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.

Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE.

Dig Dis Sci. 2019 Apr 1. doi: 10.1007/s10620-019-05604-8. [Epub ahead of print]

PMID:
30937719
2.

Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress.

Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, Iuliano N, Giordano M, Passariello N, Sasso FC, Albano E, Adinolfi LE.

Infection. 2018 Dec;46(6):793-799. doi: 10.1007/s15010-018-1185-6. Epub 2018 Jul 31.

PMID:
30066228
3.

HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.

Minichini C, Starace M, De Pascalis S, Macera M, Occhiello L, Caroprese M, Vitrone M, Iovinella V, Guerrera B, Masarone M, Coppola N.

Antivir Ther. 2018;23(7):605-609. doi: 10.3851/IMP3228. Epub 2018 Mar 5.

PMID:
29504510
4.

Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.

Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L.

J Gastroenterol Hepatol. 2018 Jul;33(7):1379-1382. doi: 10.1111/jgh.14067. Epub 2018 Feb 27.

PMID:
29228501
5.

Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.

Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE.

World J Gastroenterol. 2017 Feb 28;23(8):1458-1468. doi: 10.3748/wjg.v23.i8.1458.

6.

Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.

Ruggiero G, Marrone A, Rainone I, Boemio A, Adinolfi LE, Pasquale G, Rinaldi L, Guerrera B, Andreana L, Zampino R; Thecla Study Group.

Infez Med. 2016 Dec 1;24(4):278-286.

7.

Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.

Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A.

World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.

8.

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.

Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R.

Int J Mol Sci. 2016 May 25;17(6). pii: E803. doi: 10.3390/ijms17060803. Review.

9.

All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality.

Adinolfi LE, Guerrera B.

World J Hepatol. 2015 Oct 8;7(22):2363-8. doi: 10.4254/wjh.v7.i22.2363.

10.

Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A.

World J Gastroenterol. 2015 Feb 28;21(8):2269-80. doi: 10.3748/wjg.v21.i8.2269. Review.

11.

Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.

Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P.

World J Gastroenterol. 2014 Apr 7;20(13):3410-7. doi: 10.3748/wjg.v20.i13.3410. Review.

12.

Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE.

World J Hepatol. 2013 Oct 27;5(10):528-40. doi: 10.4254/wjh.v5.i10.528. Review.

13.

Chronic HCV infection is a risk factor of ischemic stroke.

Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A.

Atherosclerosis. 2013 Nov;231(1):22-6. doi: 10.1016/j.atherosclerosis.2013.08.003. Epub 2013 Aug 15.

PMID:
24125405
14.

Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.

Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A.

Atherosclerosis. 2012 Apr;221(2):496-502. doi: 10.1016/j.atherosclerosis.2012.01.051. Epub 2012 Feb 8.

PMID:
22385985
15.

Metastatic melanoma: an unusual presentation.

De Vita F, Giordano G, Fabozzi A, Guerrera B, Fabozzi T, Fasano M, Ferrara M, Fascione A, Di Benedetto G.

Tumori. 2011 Jan-Feb;97(1):130-2.

PMID:
21528678

Supplemental Content

Loading ...
Support Center